Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 244

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial

Open access
Packer, Douglas L., Prutkin, Jordan M., Hellkamp, Anne S., Mitchell, L. Brent, Bernstein, Robert C., Wood, Freda, Boehmer, John P., Carlson, Mark D., Frantz, Robert P., McNulty, Steve E., Rogers, Joseph G., Anderson, Jill, Johnson, George W., Walsh, Mary Norine, Poole, Jeanne E., Mark, Daniel B., Lee, Kerry L., Bardy, Gust H. · 2009 · Circulation

Abstract

Background— The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces all-cause mortality in patients with New York Heart Association class II/III heart failure and a left ventricular ejection fraction ≤35% on optimal medical therapy. Whether ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart failure deaths in this population is unknown. Methods and Results— SCD-HeFT randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy. Over a median follow-up of 45.5 months, a total of 666 deaths occurred, which were reviewed by an Events Committee and initially categorized as cardiac or noncardiac. Cardiac deaths were further adjudicated as resulting from sudden death presumed to be ventricular tachyarrhythmic, bradyarrhythmia, heart failure, or other cardiac causes. ICD therapy significantly reduced cardiac mortality compared with placebo (adjusted hazard ratio, 0.76; 95% confidence interval, 0.60 to 0.95) and tachyarrhythmia mortality (adjusted hazard ratio, 0.40; 95% confidence interval, 0.27 to 0.59) and had no impact on mortality resulting from heart failure or noncardiac causes. The cardiac and tachyarrhythmia mortality reductions were evident in subjects with New York Heart Association class II but not in subjects with class III heart failure. The reduction in tachyarrhythmia mortality with ICD therapy was similar in subjects with ischemic and nonischemic disease. Compared with placebo, amiodarone had no significant effect on any mode of death. Conclusions— ICD therapy reduced cardiac mortality and sudden death presumed to be ventricular tachyarrhythmic in SCD-HeFT and had no effect on heart failure mortality. Amiodarone had no effect on all-cause mortality or its cause-specific components, except an increase in non-cardiac mortality in class III patients. Clinical Trial Registration Information— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000609.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.853689

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 244

Metadata

Authors
Packer, D. L., Prutkin, J. M., Hellkamp, A. S., Mitchell, L. B., Bernstein, R. C., Wood, F., Boehmer, J. P., Carlson, M. D., Frantz, R. P., McNulty, S. E., Rogers, J. G., Anderson, J., Johnson, G. W., Walsh, M. N., Poole, J. E., Mark, D. B., Lee, K. L., & Bardy, G. H.
Venue
Circulation
Published
2009-12
Volume
120
Issue
22
Pages
2170-2176
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2133521252
Cited by
244
References
4
FWCI
10.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial. https://app.cochat.ai/papers/10.1161/circulationaha.109.853689
The paper
Packer, D. L., Prutkin, J. M., Hellkamp, A. S., Mitchell, L. B., Bernstein, R. C., Wood, F., Boehmer, J. P., Carlson, M. D., Frantz, R. P., McNulty, S. E., Rogers, J. G., Anderson, J., Johnson, G. W., Walsh, M. N., Poole, J. E., Mark, D. B., Lee, K. L., & Bardy, G. H. (2009). Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial. Circulation. https://doi.org/10.1161/circulationaha.109.853689

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.